» Articles » PMID: 26842924

Segmental Distribution of Some Common Molecular Markers for Colorectal Cancer (CRC): Influencing Factors and Potential Implications

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2016 Feb 5
PMID 26842924
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Proximal and distal colorectal cancers (CRCs) are regarded as distinct disease entities, evolving through different genetic pathways and showing multiple clinicopathological and molecular differences. Segmental distribution of some common markers (e.g., KRAS, EGFR, Ki-67, Bcl-2, COX-2) is clinically important, potentially affecting their prognostic or predictive value. However, this distribution is influenced by a variety of factors such as the anatomical overlap of tumorigenic molecular events, associations of some markers with other clinicopathological features (stage and/or grade), and wide methodological variability in markers' assessment. All these factors represent principal influences followed by intratumoral heterogeneity and geographic variation in the frequency of detection of particular markers, whereas the role of other potential influences (e.g., pre-adjuvant treatment, interaction between markers) remains rather unclear. Better understanding and elucidation of the various influences may provide a more accurate picture of the segmental distribution of molecular markers in CRC, potentially allowing the application of a novel patient stratification for treatment, based on particular molecular profiles in combination with tumor location.

Citing Articles

Prognostic Biomarkers of Cell Proliferation in Colorectal Cancer (CRC): From Immunohistochemistry to Molecular Biology Techniques.

Kasprzak A Cancers (Basel). 2023; 15(18).

PMID: 37760539 PMC: 10526446. DOI: 10.3390/cancers15184570.


Long-term status of predicted body fat percentage, body mass index and other anthropometric factors with risk of colorectal carcinoma: Two large prospective cohort studies in the US.

Hanyuda A, Lee D, Ogino S, Wu K, Giovannucci E Int J Cancer. 2019; 146(9):2383-2393.

PMID: 31276608 PMC: 7282530. DOI: 10.1002/ijc.32553.


International scientific communications in the field of colorectal tumour markers.

Ivanov K, Donev I World J Gastrointest Surg. 2017; 9(5):127-138.

PMID: 28603585 PMC: 5442406. DOI: 10.4240/wjgs.v9.i5.127.


Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.

Miyamoto Y, Suyama K, Baba H Int J Mol Sci. 2017; 18(4).

PMID: 28368335 PMC: 5412337. DOI: 10.3390/ijms18040752.

References
1.
Garrity M, Burgart L, Mahoney M, Windschitl H, Salim M, Wiesenfeld M . Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol. 2004; 22(9):1572-82. DOI: 10.1200/JCO.2004.10.042. View

2.
Gawlick U, Lu K, Douthit M, Diggs B, Schuff K, Herzig D . Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. Am J Surg. 2013; 205(5):608-12. DOI: 10.1016/j.amjsurg.2013.01.029. View

3.
Ruder E, Laiyemo A, Graubard B, Hollenbeck A, Schatzkin A, Cross A . Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011; 106(7):1340-50. PMC: 3183504. DOI: 10.1038/ajg.2011.38. View

4.
Iacopetta B . Are there two sides to colorectal cancer?. Int J Cancer. 2002; 101(5):403-8. DOI: 10.1002/ijc.10635. View

5.
Blons H, Emile J, le Malicot K, Julie C, Zaanan A, Tabernero J . Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol. 2014; 25(12):2378-2385. DOI: 10.1093/annonc/mdu464. View